Key Highlights
• Primary Endpoint Met With Strong Effect Size: Epcoritamab plus lenalidomide significantly improved PFS over R-GemOx in relapsed/refractory DLBCL.
• 60% Reduction in Progression or Death Risk: The combination regimen markedly outperformed the chemotherapy-based standard of care, R-GemOx.
• Chemotherapy-Free Treatment Option: The regimen offers a non-chemotherapy alternative, a key benefit for older or frailer relapsed/refractory patients.
Genmab A/S (NASDAQ: GMAB) shares advanced approximately 6% after the company announced that its pivotal Phase 3 EPCORE DLBCL-4 trial met its primary endpoint, demonstrating that fixed-duration epcoritamab in combination with lenalidomide significantly improved progression-free survival (PFS) compared to the chemotherapy regimen R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The headline result from the trial was striking: the epcoritamab-lenalidomide combination reduced the risk of disease progression or death by 60% relative to R-GemOx, a chemotherapy-based regimen that has long served as a standard treatment option for this difficult-to-treat patient population. DLBCL is the most common type of non-Hodgkin lymphoma, and outcomes for patients who relapse after frontline therapy or who are refractory to initial treatment have historically remained poor, underscoring the clinical significance of this result.
Perhaps equally important from both a clinical and commercial perspective, the epcoritamab-lenalidomide regimen represents a chemotherapy-free treatment alternative, a distinction that carries substantial value for patients, many of whom are older, more frail, or otherwise poor candidates for the toxicity burden associated with traditional cytotoxic chemotherapy combinations like R-GemOx. The ability to offer a comparably or more effective treatment option without the added systemic toxicity of chemotherapy could meaningfully shift treatment paradigms in the relapsed/refractory DLBCL setting.
Epcoritamab, marketed under the brand name Epkinly in certain approved indications, is a bispecific antibody engineered to simultaneously bind CD3 on T-cells and CD20 on malignant B-cells, redirecting the patient's own immune system to target and destroy lymphoma cells. Its combination with lenalidomide, an established immunomodulatory agent with a long track record in B-cell malignancies, appears to produce a synergistic clinical benefit, as reflected in the robust PFS improvement observed in EPCORE DLBCL-4.
Genmab and its development partner are expected to leverage these robust Phase 3 results to support regulatory engagement seeking expanded approval for the epcoritamab-lenalidomide combination in this relapsed/refractory DLBCL setting. Given the magnitude of the reported risk reduction, a 60% decrease in progression or death risk represents a clinically meaningful and statistically compelling benefit, the data could position this combination as a new standard-of-care contender for patients who have exhausted or are unsuitable for traditional chemotherapy approaches.
The approximately 6% rise in Genmab shares reflects the market's recognition of both the clinical significance and the commercial potential of these results. With epcoritamab already established as a key growth driver within Genmab's broader antibody therapeutics portfolio, continued positive readouts across additional indications and combination regimens, such as this one, reinforce the asset's strategic importance to the company's long-term oncology franchise.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...